Anaveon was founded in December 2017 by leading experts in the field of immunotherapy, Onur Boyman, Professor and Chair in the Department of Immunology at the University of Zurich and a recognised IL-2 biology expert, and Andreas Katopodis, previously Director at the Autoimmunity, Transplantation & Inflammation Group at the Novartis Institutes for BioMedical Research. Anaveon was founded with initial seed capital from the UZH Life Sciences Fund which will convert in the Series A financing and additional funding from BaseLaunch, a healthcare accelerator operated by BaselArea.swiss.
The Company is developing a selective IL-2 Receptor Agonist, a type of protein that could therapeutically enhance a patient’s immune system to respond to tumours. In the body, human IL-2 stimulates a type of immune cell, called a T-cell, to multiply and become activated. Under certain situations, T-cells are able to attack tumours and, consistent with this, human IL-2 is already approved as a medicine for the treatment of metastatic melanoma and renal cancer.